Gut microbiome modulates efficacy of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Yu, Shengnan, Qin, Shuang, Liu, Qian, Xu, Hanxiao, Zhao, Weiheng, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870075/
https://www.ncbi.nlm.nih.gov/pubmed/29580257
http://dx.doi.org/10.1186/s13045-018-0592-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870075/
https://www.ncbi.nlm.nih.gov/pubmed/29580257
http://dx.doi.org/10.1186/s13045-018-0592-6

Ejemplares similares